In a strategic move to accelerate the global reach of its oncology pipeline, 1cBio has announced a significant licensing agreement with Lee’s Pharmaceutical. The deal grants Lee’s Pharm exclusive rights to develop and commercialize OC-3, an innovative drug candidate, across China and designated markets in Southeast Asia.
The partnership, which includes a comprehensive drug supply manufacturing agreement, represents a major financial milestone for 1cBio. Under the terms of the contract, the company stands to receive up to $27 million, a figure encompassing upfront payments, development and sales-based milestones, and future royalties on product performance.
At the center of the agreement is OC-3, a potent poly(ADP-ribose) polymerase 1 (PARP1) inhibitor. 1cBio describes the drug as a potentially first-in-class therapy designed to combat cancers characterized by defects in DNA homologous recombination repair. This includes various aggressive malignancies—such as breast, ovarian, prostate, and pancreatic cancers—that often carry mutations in critical DNA repair genes like BRCA1, BRCA2, and PALB2. Early preclinical models have shown that OC-3 delivers robust anticancer activity, raising hopes that it could provide a superior alternative for patients with limited treatment options.
The division of labor under the agreement is designed to leverage the core strengths of both firms. While Lee’s Pharm assumes responsibility for conducting Good Laboratory Practice (GLP) safety studies and managing the manufacturing activities necessary to secure regulatory approval in China and neighboring territories, the partnership also provides 1cBio with a distinct advantage. 1cBio retains full access to all data generated under the agreement, which the company can utilize to support its own Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA).
“This agreement provides 1cBio a valued China-based drug development and commercialization partner for OC-3,” said 1cBio CEO Andrew Protter, PhD. “1cBio collaborates with a team [with] a robust oncology group, strong manufacturing capabilities, and a proven ability to advance assets.”
The partnership is seen as a major endorsement for 1cBio, reinforcing the developer’s position as a key player in the creation of innovative therapies for serious and underserved conditions. For Lee’s Pharmaceutical, the move is equally ambitious. Benjamin Li, Founder and Director of Lee’s Pharm, expressed confidence in the asset’s potential, noting that OC-3 possesses a “differentiated profile” that could translate to meaningful improvements in both patient safety and clinical efficacy.
Industry analysts suggest that by offloading the development hurdles in the Asian market to a proven local partner, 1cBio can streamline its focus on the U.S. regulatory pathway. As both companies prepare for upcoming development phases, the success of this collaboration will be closely watched, as it could mark a significant breakthrough in the treatment of DNA-repair-deficient cancers.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
